openPR Logo
Press release

Non-Hodgkin lymphoma treatment Market Size, Trends, Global Industry Report to 2019-2025

06-29-2020 09:58 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Orion Market Research

The global Non-Hodgkin lymphoma treatment market is anticipated to grow at a significant CAGR during the forecast period. The Non-Hodgkin lymphoma cancer is more common with high prevalence which will drive the Non-Hodgkin lymphoma treatment industry considerably. Non-Hodgkin lymphoma shows constitutional symptoms as well as hepatosplenomegaly symptoms. Constitutional symptoms include weight loss, hyperhidrosis, generalized hyperhidrosis, chronic pain, fatigue, and malaise. Whereas hepatosplenomegaly symptoms include abdominal pain, swelling or tenderness, nausea and vomiting, fever.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/non-hodgkin-lymphoma-treatment-market

Some lymphomas will secrete Immunoglobulin M (IgM) which leads to hyperviscosity syndrome as well as autoimmune cytopenia. Hence, rise in autoimmune diseases across the globe will significantly drive the Non-Hodgkin lymphoma treatment market. The non-Hodgkin lymphomas also secrete gammaglobulinemia which leads to infectious diseases. Thus, the increasing infection will also drive the market.

A Full Report of Global Non-Hodgkin lymphoma treatment Market is Available at: https://www.omrglobal.com/industry-reports/non-hodgkin-lymphoma-treatment-market

Additionally, Non-Hodgkin lymphoma is the second most common cancer in patients with AIDS. According to the World Health Organization, 37.9 million people are living with HIV in 2018 across the globe. People living with HIV are about ten times more likely to develop Non-Hodgkin lymphoma than people without HIV. Hence the increasing AIDS cases across the globe is likely to drive the Non-Hodgkin lymphoma treatment market significantly.

Moreover, the risk of developing Non-Hodgkin lymphoma is significantly high after organ transplant as the patient’s immunity becomes weak after the transplantation. Therefore, the increase in organ transplantation activities will also fuel the Non-Hodgkin lymphoma treatment market. In addition to this, immunosuppressed as well as congenital immune deficiency patients are also at high risk of developing Non-Hodgkin lymphoma. Hence, the patient pool of these kind of diseases will significantly impact the Non-Hodgkin lymphoma treatment industry size.

Additionally, the increasing use of radiation and chemotherapy as the first line of treatment in lymphoma cancer will also impact the Non-Hodgkin lymphoma treatment market growth. Besides, the development and advancements of therapies such as CAR-T cells are also anticipated to drive the market during the forecast period.

Global Non-Hodgkin Lymphoma Treatment Market- Segmentation

By Cell Type

B-Cell
T-Cell

By Therapy Type

Chemotherapy
Radiation
Others

Global Non-Hodgkin Lymphoma Treatment Market- Segment by Region

North America

US
Canada

Europe

Germany
UK
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific

Rest of the World

Company Profiles

AbbVie Inc.
Amgen Inc.

AstraZeneca PLC

Bayer AG
Bristol Myers Squibb Co.
Eli Lilly and Co.
Epizyme, Inc.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Johnson & Johnson Services Inc.

Merck & Co., Inc.

Nordic Nanovector ASA
Novartis International AG
Pfizer Inc.
Sanofi SA

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/non-hodgkin-lymphoma-treatment-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Hodgkin lymphoma treatment Market Size, Trends, Global Industry Report to 2019-2025 here

News-ID: 2081754 • Views:

More Releases from Orion Market Research

Healthcare Distribution Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
Healthcare Distribution Market Size, Trends, Latest Insights, Analysis and Forec …
Global healthcare distribution market is anticipated to grow at a CAGR of 6.7% during the forecast period (2024-2031). Globally, a considerable increase in the burden of chronic diseases pressuring countries to adopt effective and efficient distribution of healthcare products. Commonly prevailing chronic diseases include heart attacks and strokes, cancer such as breast and colon, diabetes, epilepsy and seizures, obesity, and oral health issues. To learn more about this report request
Prediabetes Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
Prediabetes Market Size, Trends, Latest Insights, Analysis and Forecast 2024-203 …
Global prediabetes market is anticipated to grow at a CAGR of 7.2% during the forecast period (2024-2031). A major factor supporting the growth of the market is the increasing product expansion and new drugs in the market. For instance, in January 2024, Novo Nordisk announced the launch of its Wegovy, a GLP-1 analog in the UK. This drug can be prescribed to people with prediabetes and for weight loss purposes.
Rapid Test Market Increasing Demand, Growth Analysis and Future Outlook by 2031
Rapid Test Market Increasing Demand, Growth Analysis and Future Outlook by 2031
The global rapid test market is anticipated to grow at a considerable CAGR of 8.2% during the forecast period (2024-2031). The increasing government initiatives for diagnosing infectious diseases owing to the growing prevalence of infectious diseases and the key developments by the market players. In order to monitor the infection rate of specific pathogens, infection monitoring and surveillance programs have grown over the past few several years. Rapid diagnostic
AI in Patient Engagement Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
AI in Patient Engagement Market Size, Trends, Latest Insights, Analysis and Fore …
Global AI in patient engagement market is anticipated to grow at a CAGR of 21.0 % during the forecast period (2024-2031). AI-powered communication tools support patients by addressing their inquiries, scheduling appointments, and providing information about their health conditions and treatments. These tools enhance patient engagement, improve access to healthcare information, and streamline administrative processes for healthcare providers. Furthermore, AI algorithms analyze large datasets, including electronic health records (EHRs), medical

All 5 Releases


More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral